Matsui K, Kuriyama K, Kobayashi M, et al. - In the treatment of abnormal eating behavior in cases with sleep-related eating disorder (SRED) and/or night eating syndrome (NES), the effectiveness of ramelteon was ascertained in this retrospective analysis. Between November 2013 and November 2018, the medical records of patients with SRED/NES at Yoyogi Sleep Disorder Center were retrospectively examined. When the frequency of nighttime eating per week decreased to less than half of that before treatment, researchers classified patients as ramelteon treatment responders. In the analysis, 49 patients were enrolled, 42.9% of whom were identified as responders. This study’s findings demonstrate that ramelteon is a candidate for treatment of SRED/NES. The outcomes considered that the impacts of ramelteon might have occurred primarily through the reduction of benzodiazepine derivatives and Z-drug rather than through the improvement of sleep-wake rhythm dysregulation. In the responder group vs the non-responder group , significantly more patients were using benzodiazepine derivatives and Z-drugs before treatment and those with coexisting delayed sleep-wake phase disorder. From baseline to post-ramelteon treatment, the mean dose of benzodiazepine derivatives and Z-drugs significantly decreased within the responder group, which was a trend was not seen in the non-responder group.